MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Pfizer Cash Conversion Cycle 2011-2026 | PFE
Annual Cash Conversion Cycle Pfizer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 189 | 155 | 110 | 70.5 | 86.3 | 241 | 230 | 170 | 173 | 144 | 228 | 149 | 178 | 224 | 220 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 241 | 70.5 | 171 |
Quarterly Cash Conversion Cycle Pfizer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 214 | 221 | 280 | 177 | 238 | 205 | 117 | 187 | 110 | - | 119 | 92.7 | 80.3 | - | 82 | 108 | 146 | - | 240 | 260 | 229 | - | 205 | 204 | 188 | - | 151 | 143 | 160 | - | 151 | 158 | - | - | - | - | - | - | - | - | - | - | - | 7.49 K | 9.06 K | - | 185 | 8.49 K | 9.74 K | - | 205 | 192 | 173 | - | 150 | 144 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.74 K | 80.3 | 1.12 K |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K |  USA |
 |
Alnylam Pharmaceuticals
ALNY
|
46.6 | $ 333.39 | -1.77 % | $ 43.7 B | USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
205 | $ 21.68 | 1.4 % | $ 1.01 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
-1.83 K | - | -5.16 % | $ 5.39 M | USA |
 |
Akebia Therapeutics
AKBA
|
42 | - | - | $ 399 M | USA |
 |
Aquestive Therapeutics
AQST
|
-172 | $ 4.24 | 2.17 % | $ 453 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
158 | $ 24.58 | -2.03 % | $ 3.13 B | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
340 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
119 | $ 1.49 | 0.68 % | $ 397 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Caladrius Biosciences
CLBS
|
164 | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
-3.74 K | $ 33.87 | 1.62 % | $ 2.25 B | USA |
 |
Clearside Biomedical
CLSD
|
-1.67 K | - | - | $ 25.3 M | USA |
 |
bluebird bio
BLUE
|
-54.4 | - | - | $ 546 M | USA |
 |
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B | Britain |